Logistic regression models for induction course thrombosis and bleeding
| . | Univariate model . | Multivariate model . | ||
|---|---|---|---|---|
| OR (95% CI) . | P value . | OR (95% CI) . | P value . | |
| Induction thrombosis | ||||
| Prophylaxis strategy | ||||
| AT monitoring: yes vs no | 1.076 (0.509-2.274) | .85 | ||
| AT repletion: yes vs no | 0.734 (0.304-1.773) | .49 | ||
| Prophylactic anticoagulation: yes vs no | 1.275 (0.490-3.316) | .62 | ||
| Cryoprecipitate transfusion: yes vs no | 1.128 (0.518-2.456) | .76 | ||
| FFP transfusion: yes vs no | 2.311 (0.787-6.789) | .13 | ||
| Age at diagnosis: ≥40 vs 18-39 y | 0.954 (0.444-2.049) | .90 | ||
| Sex: female vs male | 0.811 (0.373-1.764) | .60 | ||
| Smoking status | .17 | |||
| Current smoker vs never smoker | 1.409 (0.395-5.026) | |||
| Former smoker vs never smoker | 2.229 (0.964-5.150) | |||
| Type of steroid in induction | .83 | |||
| Dexamethasone vs prednisone | 1.276 (0.577-2.823) | |||
| Other/none/not available vs prednisone | 1.083 (0.340-3.449) | |||
| VTE and bleeding risk factors | ||||
| Obesity: yes vs no | 0.767 (0.285-2.064) | .60 | ||
| Renal failure: yes vs no | 1.974 (0.252-15.476) | .52 | ||
| Heart disease: yes vs no | 3.438 (1.101-10.737) | .03 | ||
| Respiratory disease: yes vs no | 4.916 (1.051-23.006) | .04 | ||
| Bleeding condition: yes vs no | 0.437 (0.019-9.983) | .60 | ||
| Other cancers: yes vs no | 0.580 (0.098-3.428) | .55 | ||
| Active infection: yes vs no | 2.040 (0.548-7.596) | .29 | ||
| Menstrual suppression: yes vs no | 0.623 (0.104-3.718) | .60 | ||
| Therapeutic anticoagulation: yes vs no | 2.765 (0.534-14.305) | .23 | ||
| Type of ALL | .43 | |||
| B cell vs T cell | 0.610 (0.283-1.311) | |||
| Other vs T cell | 0.457 (0.017-12.647) | |||
| Type of CVC | .01 | .01 | ||
| PICC vs CVC | 4.112 (1.622-10.427) | 4.112 (1.622-10.427) | ||
| Port vs CVC | 0.470 (0.023-9.678) | 0.470 (0.023-9.678) | ||
| PICC vs port | 8.757 (0.456-168.349) | 8.757 (0.456-168.349) | ||
| Laboratory counts | ||||
| Platelet nadir, ×109/L | .94 | |||
| 10-30 vs <10 | 0.898 (0.344-2.343) | |||
| >30 vs <10 | 1.081 (0.463-2.523) | |||
| Fibrinogen nadir, mg/dL | .45 | |||
| 100-150 vs <100 | 0.645 (0.216-1.928) | |||
| >150 vs <100 | 0.545 (0.184-1.611) | |||
| Induction bleeding | ||||
| Prophylaxis strategy | ||||
| AT repletion: yes vs no | 0.338 (0.059-1.934) | .22 | ||
| Prophylactic anticoagulation: yes vs no | 0.165 (0.009-2.947) | .22 | ||
| Cryoprecipitate transfusion: yes vs no | 0.763 (0.243-2.395) | .64 | ||
| FFP transfusion: yes vs no | 4.075 (1.054-15.752) | .04 | ||
| Age at diagnosis: ≥40 vs 18-39 y | 1.586 (0.513-4.904) | .42 | ||
| Sex: female vs male | 2.237 (0.714-7.008) | .17 | ||
| Smoking status | .19 | |||
| Current smoker vs never smoker | 3.687 (0.903-15.044) | |||
| Former smoker vs never smoker | 1.546 (0.400-5.976) | |||
| Type of steroid in induction | .35 | |||
| Dexamethasone vs prednisone | 2.542 (0.686-9.421) | |||
| Other/none/not available vs prednisone | 2.481 (0.454-13.553) | |||
| VTE and bleeding risk factors | ||||
| Obesity: yes vs no | 1.478 (0.409-5.342) | .55 | ||
| Renal failure: yes vs no | 4.682 (0.609-35.982) | .14 | ||
| Heart disease: yes vs no | 3.630 (0.780-16.884) | .10 | ||
| Respiratory disease: yes vs no | 3.942 (0.539-28.825) | .18 | ||
| Bleeding condition: yes vs no | 1.209 (0.051-28.485) | .91 | ||
| Other cancers: yes vs no | 0.484 (0.025-9.381) | .63 | ||
| Active infection: yes vs no | 3.966 (0.842-18.682) | .08 | 5.084 (1.034-24.997) | .05 |
| Menstrual suppression: yes vs no | 4.344 (0.908-20.769) | .07 | 5.084 (1.034-24.997) | .05 |
| Therapeutic anticoagulation: yes vs no | 0.916 (0.042-19.890) | .96 | ||
| Type of ALL | .93 | |||
| B cell vs T cell | 0.885 (0.270-2.904) | |||
| Other vs T cell | 1.569 (0.052-47.240) | |||
| Type of CVC | .48 | |||
| PICC vs CVC | 2.143 (0.578-7.942) | |||
| Port vs CVC | 0.926 (0.041-20.968) | |||
| PICC vs port | 2.314 (0.113-47.569) | |||
| Laboratory counts | ||||
| Platelet nadir, ×109/L | .21 | |||
| 10-30 vs <10 | 1.523 (0.459-5.051) | |||
| >30 vs <10 | 0.284 (0.046-1.745) | |||
| Fibrinogen nadir, mg/dL | .18 | |||
| 100-150 vs <100 | 3.305 (0.912-11.977) | |||
| >150 vs <100 | 1.264 (0.277-5.765) | |||
| . | Univariate model . | Multivariate model . | ||
|---|---|---|---|---|
| OR (95% CI) . | P value . | OR (95% CI) . | P value . | |
| Induction thrombosis | ||||
| Prophylaxis strategy | ||||
| AT monitoring: yes vs no | 1.076 (0.509-2.274) | .85 | ||
| AT repletion: yes vs no | 0.734 (0.304-1.773) | .49 | ||
| Prophylactic anticoagulation: yes vs no | 1.275 (0.490-3.316) | .62 | ||
| Cryoprecipitate transfusion: yes vs no | 1.128 (0.518-2.456) | .76 | ||
| FFP transfusion: yes vs no | 2.311 (0.787-6.789) | .13 | ||
| Age at diagnosis: ≥40 vs 18-39 y | 0.954 (0.444-2.049) | .90 | ||
| Sex: female vs male | 0.811 (0.373-1.764) | .60 | ||
| Smoking status | .17 | |||
| Current smoker vs never smoker | 1.409 (0.395-5.026) | |||
| Former smoker vs never smoker | 2.229 (0.964-5.150) | |||
| Type of steroid in induction | .83 | |||
| Dexamethasone vs prednisone | 1.276 (0.577-2.823) | |||
| Other/none/not available vs prednisone | 1.083 (0.340-3.449) | |||
| VTE and bleeding risk factors | ||||
| Obesity: yes vs no | 0.767 (0.285-2.064) | .60 | ||
| Renal failure: yes vs no | 1.974 (0.252-15.476) | .52 | ||
| Heart disease: yes vs no | 3.438 (1.101-10.737) | .03 | ||
| Respiratory disease: yes vs no | 4.916 (1.051-23.006) | .04 | ||
| Bleeding condition: yes vs no | 0.437 (0.019-9.983) | .60 | ||
| Other cancers: yes vs no | 0.580 (0.098-3.428) | .55 | ||
| Active infection: yes vs no | 2.040 (0.548-7.596) | .29 | ||
| Menstrual suppression: yes vs no | 0.623 (0.104-3.718) | .60 | ||
| Therapeutic anticoagulation: yes vs no | 2.765 (0.534-14.305) | .23 | ||
| Type of ALL | .43 | |||
| B cell vs T cell | 0.610 (0.283-1.311) | |||
| Other vs T cell | 0.457 (0.017-12.647) | |||
| Type of CVC | .01 | .01 | ||
| PICC vs CVC | 4.112 (1.622-10.427) | 4.112 (1.622-10.427) | ||
| Port vs CVC | 0.470 (0.023-9.678) | 0.470 (0.023-9.678) | ||
| PICC vs port | 8.757 (0.456-168.349) | 8.757 (0.456-168.349) | ||
| Laboratory counts | ||||
| Platelet nadir, ×109/L | .94 | |||
| 10-30 vs <10 | 0.898 (0.344-2.343) | |||
| >30 vs <10 | 1.081 (0.463-2.523) | |||
| Fibrinogen nadir, mg/dL | .45 | |||
| 100-150 vs <100 | 0.645 (0.216-1.928) | |||
| >150 vs <100 | 0.545 (0.184-1.611) | |||
| Induction bleeding | ||||
| Prophylaxis strategy | ||||
| AT repletion: yes vs no | 0.338 (0.059-1.934) | .22 | ||
| Prophylactic anticoagulation: yes vs no | 0.165 (0.009-2.947) | .22 | ||
| Cryoprecipitate transfusion: yes vs no | 0.763 (0.243-2.395) | .64 | ||
| FFP transfusion: yes vs no | 4.075 (1.054-15.752) | .04 | ||
| Age at diagnosis: ≥40 vs 18-39 y | 1.586 (0.513-4.904) | .42 | ||
| Sex: female vs male | 2.237 (0.714-7.008) | .17 | ||
| Smoking status | .19 | |||
| Current smoker vs never smoker | 3.687 (0.903-15.044) | |||
| Former smoker vs never smoker | 1.546 (0.400-5.976) | |||
| Type of steroid in induction | .35 | |||
| Dexamethasone vs prednisone | 2.542 (0.686-9.421) | |||
| Other/none/not available vs prednisone | 2.481 (0.454-13.553) | |||
| VTE and bleeding risk factors | ||||
| Obesity: yes vs no | 1.478 (0.409-5.342) | .55 | ||
| Renal failure: yes vs no | 4.682 (0.609-35.982) | .14 | ||
| Heart disease: yes vs no | 3.630 (0.780-16.884) | .10 | ||
| Respiratory disease: yes vs no | 3.942 (0.539-28.825) | .18 | ||
| Bleeding condition: yes vs no | 1.209 (0.051-28.485) | .91 | ||
| Other cancers: yes vs no | 0.484 (0.025-9.381) | .63 | ||
| Active infection: yes vs no | 3.966 (0.842-18.682) | .08 | 5.084 (1.034-24.997) | .05 |
| Menstrual suppression: yes vs no | 4.344 (0.908-20.769) | .07 | 5.084 (1.034-24.997) | .05 |
| Therapeutic anticoagulation: yes vs no | 0.916 (0.042-19.890) | .96 | ||
| Type of ALL | .93 | |||
| B cell vs T cell | 0.885 (0.270-2.904) | |||
| Other vs T cell | 1.569 (0.052-47.240) | |||
| Type of CVC | .48 | |||
| PICC vs CVC | 2.143 (0.578-7.942) | |||
| Port vs CVC | 0.926 (0.041-20.968) | |||
| PICC vs port | 2.314 (0.113-47.569) | |||
| Laboratory counts | ||||
| Platelet nadir, ×109/L | .21 | |||
| 10-30 vs <10 | 1.523 (0.459-5.051) | |||
| >30 vs <10 | 0.284 (0.046-1.745) | |||
| Fibrinogen nadir, mg/dL | .18 | |||
| 100-150 vs <100 | 3.305 (0.912-11.977) | |||
| >150 vs <100 | 1.264 (0.277-5.765) | |||
OR of >1 indicates that event is more likely to occur with the first variable than the second, whereas OR of <1 indicates an event is more likely to occur with the second variable than the first.